New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 5, 2014
05:49 EDTPSTIPluristem CEO says muscle injury study suggests PLX-PAD effective treatment
Pluristem Therapeutics issued a Letter to Shareholders from its CEO, Zami Aberman. Aberman stated, "We have started 2014 with strong momentum on many fronts, including advancements in our clinical pipeline and regulatory approvals surrounding our cell therapy production methods and new manufacturing facility. The outstanding safety and efficacy results of our Phase I/II muscle injury study announced in January suggest that PLX-PAD cells may be effective in the treatment of muscle and tendon injuries. We analyzed the potential for a variety of orthopedic indications. Based on our findings and in keeping with our strategy, we have decided to move forward with at least two clinical indications, which will be announced in the next few weeks. Enrollment of the Phase II intermittent claudication, or IC, study is moving forward in the U.S., Germany and Israel and we expect to initiate enrollment in South Korea shortly."
News For PSTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 21, 2014
05:09 EDTPSTIPluristem moves to large-scale manufacturing after second product line completed
Pluristem Therapeutics announced that it has completed development of its second major product line, and can now begin manufacturing the cells on a large-scale at its state-of-the art facility in order to meet demand for anticipated studies in a range of hematologic conditions. This second cell product candidate, called PLX-RAD, was created using Pluristem's proprietary three dimensional cell expansion technology platform. The company's first product, PLX-PAD, is already in clinical trials for the treatment of peripheral artery disease, muscle injury and pulmonary arterial hypertension. Pluristem's development plan for the PLX-RAD cells considers numerous potential clinical indications such as: enhancement of engraftment of transplanted hematopoietic stem cells for the treatment of bone marrow deficiency, which can result from immune system disorders, genetic diseases, and treatment of leukemia and other blood cancers; treatment of bone marrow deficiency in patients who have undergone chemotherapy; treatment of acute radiation syndrome, or ARS in conjunction with the U.S. National Institutes of Health's National Institute of Allergy and Infectious Diseases.
October 20, 2014
07:19 EDTPSTIIBC Life Sciences to hold a conference
Subscribe for More Information
October 14, 2014
16:42 EDTPSTIPluristem Therapeutics files $200M mixed securities shelf

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use